UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers

Clinical therapeutics, 2016-01, Vol.38 (1), p.53-65

2016

Volltextzugriff (PDF)

Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age

Clinical therapeutics, 2016, Vol.38 (1), p.39-52

2016

Volltextzugriff (PDF)

The Pharmacokinetics of the CYP3A Substrate Midazolam After Steady-state Dosing of Delafloxacin

Clinical therapeutics, 2017-06, Vol.39 (6), p.1182-1190

2017

Volltextzugriff (PDF)

Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function

Journal of clinical pharmacology, 2018-04, Vol.58 (4), p.514-521

2018

Volltextzugriff (PDF)

Serum adalimumab concentration and clinical remission in patients with Crohn's disease

Inflammatory bowel diseases, 2013-05, Vol.19 (6), p.1112-1122

2013

Volltextzugriff (PDF)

Clinical Pharmacokinetics of Sulfobutylether‐β‐Cyclodextrin in Patients With Varying Degrees of Renal Impairment

Journal of clinical pharmacology, 2018-06, Vol.58 (6), p.814-822

2018

Volltextzugriff (PDF)

Pharmacokinetics of Intravenous Delafloxacin in Patients With End‐Stage Renal Disease

Journal of clinical pharmacology, 2018-07, Vol.58 (7), p.913-919

2018

Volltextzugriff (PDF)

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment

Journal of clinical pharmacology, 2017-03, Vol.57 (3), p.328-335

2017

Volltextzugriff (PDF)

Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease

Journal of Crohn's and colitis, 2012-03, Vol.6 (2), p.160-173

2012

Volltextzugriff (PDF)

Effect of Phosphate Binders and a Dietary Iron Supplement on the Pharmacokinetics of a Single Dose of Vadadustat in Healthy Adults

Clinical pharmacology in drug development, 2022-04, Vol.11 (4), p.475-485

2022

Volltextzugriff (PDF)

Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor

Clinical pharmacology in drug development, 2021-08, Vol.10 (8), p.950-958

2021

Volltextzugriff (PDF)

Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption

The Journal of pharmacology and experimental therapeutics, 2001-05, Vol.297 (2), p.638

2001

Volltextzugriff (PDF)

Tissue Factor Pathway Inhibitor Does Not Influence Inflammatory Pathways during Human Endotoxemia

The Journal of infectious diseases, 2001-06, Vol.183 (12), p.1815-1818

2001

Volltextzugriff (PDF)

Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia

Blood, 2000-02, Vol.95 (4), p.1124-1129

2000

Volltextzugriff (PDF)

Characterization of metabolites of Celecoxib in rabbits by liquid chromatography/tandem mass spectrometry

Journal of mass spectrometry., 2000-11, Vol.35 (11), p.1259-1270

2000

Volltextzugriff (PDF)

Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers

Drug metabolism and disposition, 2000-03, Vol.28 (3), p.308

2000

Volltextzugriff (PDF)

Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats

Drug metabolism and disposition, 2000-05, Vol.28 (5), p.514

2000

Volltextzugriff (PDF)

Pharmacology of cyclooxygenase-2 inhibition in the kidney

Kidney international, 2002-04, Vol.61 (4), p.1210-1219

2002

Volltextzugriff (PDF)

Pharmacokinetic Evaluation of Drug Interactions Between Vadadustat and HMG-CoA Reductase Inhibitors (Statins): PO2368

Journal of the American Society of Nephrology, 2020-10, Vol.31 (10S), p.720-720

2020

Volltextzugriff (PDF)

741 Evaluation of Potential Correlations Between Serum Adalimumab Concentration and Remission in Patients With Crohn's Disease in Classic I and II

Gastroenterology (New York, N.Y. 1943), 2010, Vol.138 (5), p.S-101-S-101

2010

Volltextzugriff (PDF)

Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib

Drug metabolism and disposition, 1999-10, Vol.27 (10), p.1133

1999

Volltextzugriff (PDF)

Disposition and Pharmacokinetics of L-N6-(1-Iminoethyl)Lysine-5-Tetrazole-Amide, a Selective iNOS Inhibitor, in Rats

Journal of pharmaceutical sciences, 2004-05, Vol.93 (5), p.1229-1240

2004

Volltextzugriff (PDF)

Plasma vitamin D metabolite levels in pregnant and nonpregnant ewes

Comparative biochemistry and physiology. A, Comparative physiology, 1990, Vol.96 (2), p.347-349

1990

Volltextzugriff (PDF)

Assay and properties of rat yolk sac 25-hydroxyvitamin D3 1.alpha.-hydroxylase

Biochemistry (Easton), 1986-11, Vol.25 (22), p.6821-6826

1986

Volltextzugriff (PDF)

Reply from the Authors

Kidney international, 2002-10, Vol.62 (4), p.1477-1478

2002

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(74)

Sprache

Englisch
(74)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers

Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age

The Pharmacokinetics of the CYP3A Substrate Midazolam After Steady-state Dosing of Delafloxacin

Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function

Serum adalimumab concentration and clinical remission in patients with Crohn's disease

Clinical Pharmacokinetics of Sulfobutylether‐β‐Cyclodextrin in Patients With Varying Degrees of Renal Impairment

Pharmacokinetics of Intravenous Delafloxacin in Patients With End‐Stage Renal Disease

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment

Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease

Effect of Phosphate Binders and a Dietary Iron Supplement on the Pharmacokinetics of a Single Dose of Vadadustat in Healthy Adults

Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor

Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption

Tissue Factor Pathway Inhibitor Does Not Influence Inflammatory Pathways during Human Endotoxemia

Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia

Characterization of metabolites of Celecoxib in rabbits by liquid chromatography/tandem mass spectrometry

Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers

Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats

Pharmacology of cyclooxygenase-2 inhibition in the kidney

Pharmacokinetic Evaluation of Drug Interactions Between Vadadustat and HMG-CoA Reductase Inhibitors (Statins): PO2368

741 Evaluation of Potential Correlations Between Serum Adalimumab Concentration and Remission in Patients With Crohn's Disease in Classic I and II

Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib

Disposition and Pharmacokinetics of L-N6-(1-Iminoethyl)Lysine-5-Tetrazole-Amide, a Selective iNOS Inhibitor, in Rats

Plasma vitamin D metabolite levels in pregnant and nonpregnant ewes

Assay and properties of rat yolk sac 25-hydroxyvitamin D3 1.alpha.-hydroxylase

Reply from the Authors

Suchergebnisse filtern